The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms

Since announcing plans to buy Bristol Myers Squibb's (BMS) drug product manufacturing facility in Couvet, Switzerland earlier this year, WuXi STA has now completed the acquisition.

The site, which represents the first facility in Europe for WuXi STA, provides tablet and capsule manufacturing and packaging capabilities.

Its enhanced supply of global medical supplies products and greater access to the European market and beyond will provide customers with more flexibility.

The company has said that combining the resources of the Couvet site with its other facilities will better support customers' long-term needs globally as they bring existing and new commercial manufacturing projects from their pipelines to the facility with the capability and capacity to supply drug products to major global markets.

Through this transaction, the CDMO has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including the recently announced new manufacturing campus in Middletown, Delaware, US.

BMS has said that although the divestiture is part of its ongoing evolution of its manufacturing network to support its product portfolio, Switzerland remains an important strategic location for the company.